Search clinical trials for: PF-07295324

Total 1301 results

Pfizer

Recruiting

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Respiratory Syncytial Virus Infections

United States, Israel, Japan, Korea, Republic of, South Africa, Argentina, Canada
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Lymphoma | Multiple Myeloma

Japan
Pfizer

Completed

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis (EMPORIA)

Plaque Psoriasis | Atopic Dermatitis

United States, Australia, Canada, Poland
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) (CARMEN CD 307)

Crohn's Disease

Spain, United States, Korea, Republic of, Australia, Romania, Hungary, Israel, Italy, Croatia, Belgium, Bulgaria, Germany, Poland, Portugal, Argentina, United Kingdom, Greece, New Zealand, Austria, Bosnia and Herzegovina, Colombia, Eston... and more
Shire

Completed

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis (TURANDOT)

Ulcerative Colitis

United States, France, Spain, Canada, Korea, Republic of, Australia, Germany, New Zealand, Serbia, Belgium, Czechia, Poland, Hungary, Austria, Bulgaria, Israel, Italy, Netherlands, South Africa, Russian Federation, Slovakia
University of Colorado, Denver
SpringWorks Therapeutics, Inc.

No longer available

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

Neoplasm | Desmoid Tumor

United States
Molecular NeuroImaging

Completed

Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects

Healthy Volunteers

United States
Pfizer

Terminated

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model (POM)

Healthy

United States
Conatus Pharmaceuticals Inc.

Completed

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

Liver Diseases | Digestive System Diseases | Hepatic Impairment

United States
Pfizer

Terminated

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease With Motor Fluctuations

United States
Pfizer

Completed

A Study In Adults With Moderate To Severe Dermatomyositis

Dermatomyositis

United States, Spain, Poland, Germany, Hungary
Sun Yat-sen University

Active, not recruiting

Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Pfizer

Completed

Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe

Healthy Volunteers

United States
Pfizer

Completed

6-week Safety and PD Study in Adults With NAFLD

Non-alcoholic Fatty Liver Disease

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Withdrawn

Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma

HIV Infection | AIDS-related Kaposi Sarcoma | Recurrent Kaposi Sarcoma
University of Sheffield
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Does Using a 'Virtual Clinic' in Urogynaecology Improve Patient Experience and Reduce Cost?

Pelvic Floor Disorders

United Kingdom
Pfizer

Completed

Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Healthy Participants

Belgium
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin

Healthy

Belgium
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Healthy | Diabetes Mellitus, Type 2 | Renal Impairment

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

Melanoma

United States
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
Pfizer

Terminated

Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234

Healthy

Belgium
Pfizer

Terminated

A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Terminated

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects

Healthy

Belgium
Pfizer

Withdrawn

A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge

Asthma
Pfizer

Terminated

A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

Sleep | Healthy Volunteers

United States
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

Healthy Volunteers

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

Multiple Myeloma | Non-Hodgkin Lymphoma

China
Pfizer
Pfizer

Recruiting

A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Sickle Cell Disease

United States, Nigeria, Kenya, Lebanon
Pfizer

Active, not recruiting

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Hemophilia B

United States, Canada, Australia, Turkey
University of the Balearic Islands
Fundació d'investigació Sanitària de les Illes Balears; Consejo Superior de...

Completed

Pelvic Floor Dysfunctions and Female Athletes (ACTITUD1)

Pelvic Floor Disorders

Spain
Yale University
National Institute on Drug Abuse (NIDA); Medical University of South Carolina; Johns Hopkins University and other collaborators

Completed

Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)

Cannabis Use Disorder

United States
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

Healthy Participants

United States
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) (CARMEN CD 305)

Crohn's Disease

United States, Australia, Romania, Israel, Italy, Croatia, South Africa, Germany, Poland, United Kingdom, Austria, Japan, Lithuania, Netherlands, Russian Federation, Serbia
Pfizer

Completed

A Trial In Patients With Advanced Cancer And Leukemia

Neoplasms by Histologic Type

United States, Italy
Pfizer

Completed

A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

Healthy Volunteers

United States
Pfizer

Completed

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

Glucose Metabolism Disorders | Metabolic Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases

United States
Pfizer

Terminated

Topical Multiple Ascending Dose Study for PF-06423264

Normal Healthy

Belgium
Pfizer

Completed

A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden
University of California, Berkeley
Alcon Research

Completed

Artificial Tears, Tear Lipids and Tear Film Dynamics (AlconAT)

Dry Eye

United States
Pfizer

Recruiting

A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

Migraine

China
Pfizer

Completed

B0151005 Open-Label Extension Study (ANDANTE II)

Crohn's Disease

United States, Denmark, Israel, Ireland, Australia, Czechia, Canada, United Kingdom, Hungary, Germany, New Zealand, Brazil, Switzerland, Belgium, France, Italy
Kathryn Wagner
Pfizer

Completed

A Trial of PF-06252616 in Ambulatory Participants With LGMD2I

LGMD2I

United States
Pfizer

Completed

PF-00489791 For The Treatment Of Raynaud's

Peripheral Vascular Disease | Raynaud's Disease

Spain, United States, Czechia, Hungary, Poland, Korea, Republic of, Canada, Mexico, Germany, Colombia, Sweden
Conatus Pharmaceuticals Inc.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Terminated

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy (AH)

Alcoholic Hepatitis

United States
Pfizer

Withdrawn

A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer

Terminated

A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Advanced Non-Hematologic Malignancies

United States, United Kingdom
Pfizer

Terminated

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

Cachexia

United States

Search clinical trials for: PF-07295324

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations